Cross-Sector entity
pharma is the sole category represented across all 1 tracked stories. ECOsynthesis is most often covered alongside Alison Moore, which appears in 1 of these 1 story. The tracked stories average 9 original sources each. ECOsynthesis appears in 1 tracked Cross-Sector story from March 12, 2026.
1 verified story tracked
Last mentioned: Mar 12, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. ECOsynthesis is most often covered alongside Alison Moore, which appears in 1 of these 1 story. The tracked stories average 9 original sources each. ECOsynthesis appears in 1 tracked Cross-Sector story from March 12, 2026.
Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering ECOsynthesis. Shared-story counts are live from our verified record — not editorial picks.
Q4 2025 earnings for specialized biotech firms reveal a sector-wide shift toward high-margin manufacturing and strategic divestitures. While Codexis capitalizes on its Merck partnership and ECOsynthesis platform, Elutia has cleared its debt through an $88 million divestiture to Boston Scientific.
